Navigation Links
Advanced Life Sciences Announces Supplemental Efficacy Data from,First Pivotal Phase 3 Pneumonia Clinical Trial

mycin 91.5% (205/224) compared to Biaxin(R) 95.9% (212/221) [-9.1, +0.3] p=0.0775). Based on the 95.9% clinical cure rate for Biaxin(R) being 90% or greater, a delta value of 10% or less on the lower bound and greater than zero on the upper bound [-9.1, +0.3] establishes non-inferiority. Under this analysis, the Company met the non-inferiority endpoint of per protocol clinical cure rate. Since p>0.05, there is not a statistically significant difference between cethromycin and Biaxin(R), which supports non-inferiority.

Supplemental Data

The Company today confirmed supplemental efficacy data with its clinical research organization and announced results in the following endpoints:

    -- Modified intent-to-treat clinical cure rate -- cethromycin 82.9%

       (213/257) compared to Biaxin(R) 88.5% (224/253) [-11.9, +0.6]

       (p=0.0769).  Based on the 88.5% clinical cure rate for Biaxin(R) being

       between 80% and 90%, a delta value of 15% or less on the lower bound

       and greater than zero on the upper bound [-11.9, +0.6] establishes

       non-inferiority.  Under this analysis, the study met the endpoint of

       modified intent-to-treat clinical cure rate.  Since p>0.05, there is

       not a statistically significant difference between cethromycin and

       Biaxin(R), which supports non-inferiority.

    -- Per protocol radiographic success rate -- cethromycin 94.2% (211/224)

       compared to Biaxin(R) 95.9% (212/221) [-6.0, +2.5] (p=0.5130).  Based

       on the 95.9% clinical cure rate for Biaxin(R) being 90% or greater, a

       delta value of 10% or less on the lower bound and greater than zero on

       the upper bound [-6.0, +2.5] establishes non-inferiority.  Under this

       analysis, the study met the endpoint of per protocol radiographic

       success rate.  Since p>0.05, there is not a statistically significant

       difference between cethromycin and Biaxin(R), which supports non-

       inferiority
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
3. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
4. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
5. Progenics and Wyeth Announce Positive Results from Three-Month Clinical-Extension Study of Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Advanced Illness
6. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
7. Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinsons Disease
8. Advanced Viral Research Corp. Announces Positive Preliminary Findings from Ongoing Phase II Dermatological Study
9. Clinical Data Reported on Vidaza in Hematologic Malignancies and Advanced Solid Tumors
10. Updated Study Results Reinforce Survival Benefit of Taxotere (Docetaxel) for Men with Advanced, Hormone-Resistant Prostate Cancer
11. GSKS Pazopanib Shows Positive Results in Patients with Advanced Renal Cell Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma
Post Your Comments:
(Date:1/23/2015)... , Jan. 23, 2015  Today the U.S. Food and ... for the prevention of serogroup B meningococcal disease ... Pfizer,s vaccine Trumenba®, which received FDA approval in October, ... devastating disease. "I have heard over ...
(Date:1/23/2015)... lot of discussion in the medical community revolves around figuring ... conditions. As medical science advances, doctors and surgeons often feel ... consider to be more cutting edge. Yet, when it comes ... treatment that stands out as the best solution in all ...
(Date:1/23/2015)... , Jan. 23, 2015  The Partnership to Fight Chronic Disease (PFCD) ... health care leaders and a new study analyzing the impact of ... is a nationwide coalition working to educate policy makers and the ... the Capitol was focused on how the Iowa ...
Breaking Medicine Technology:The National Meningitis Association (NMA) Applauds FDA Approval of Second Vaccine To Protect Against Serogroup B Meningococcal Disease 2No One-Size-Fits-All Remedy for Hernia Correction 2New research shows Iowa health exchange would benefit from improvements 2New research shows Iowa health exchange would benefit from improvements 3
... , CLEVELAND, Nov. 30 DATATRAK International, Inc. (OTCQX: ... solutions for the clinical trials industry, today announced that PFC ... PFC will now have the ability to contract for DATATRAK,s ... product suite. In addition, PFC will also have access ...
... Breast-Specific Gamma Imaging (BSGI) has been proven to be ... carcinoma in situ (DCIS), a difficult to diagnose breast cancer. ... lesions independent of tissue density and discover very early stage ... of the Radiological Society of North America (RSNA), BSGI is ...
Cached Medicine Technology:PFC Pharma Joins DATATRAK's CRO Connect Program 2PFC Pharma Joins DATATRAK's CRO Connect Program 3PFC Pharma Joins DATATRAK's CRO Connect Program 4Breast-Specific Gamma Imaging Proves Highly Sensitive for the Detection of Ductal Carcinoma In Situ 2
(Date:1/22/2015)... Lynchburg, Va. (PRWEB) January 22, 2015 Liberty ... Health Counseling (M.A.) program from the Council for ... The program, part of Liberty’s Center for Counseling & ... Hawkins, founding dean of the university’s new School of Behavioral ...
(Date:1/22/2015)... Woodloch Pines, an all-inclusive family resort ... TripAdvisor as the number one best large hotel for families ... world for their annual Travelers’ Choice Awards. , TripAdvisor ... website is home to millions of unbiased and honest traveler ...
(Date:1/22/2015)... a seasoned and trusted leader who consistently delivers trendy dresses ... it lead the wedding dress industry into the future. Today, ... the global market. , “The CEO of VogueQueen is uniquely ... continuing the goal of operational excellence and giving back to ...
(Date:1/22/2015)... Blue Cross and Blue Shield of Minnesota ... it means to “Live Fearless.” , The “Faces ... their stories about how they or someone they know has ... living in the moment. By telling these types of stories ...
(Date:1/22/2015)... Juvent Sports ( http://www.juventsports.com ) and David Leadbetter ... to bestow a Juvent Sports Achievement award upon an ... The award commemorated and congratulated McKitrick for her record ... her first amateur tournament in 1979 and most recently ...
Breaking Medicine News(10 mins):Health News:Liberty University's Resident Master’s Counseling Program Receives CACREP Accreditation 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 3Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3
... University and pediatric specialists at Baylor College of Medicine have ... as passkeys that allows drugs to enter cancer cells. ... of the journal Organic and Biomolecular Chemistry. ,All ... Cell walls, or membranes, form a protective cocoon around the ...
... that attacks healthy young people and can kill within 24 hours.// ... attempts to find a cure for the virulent disease, PVL-MRSA, that ... responsible for two deaths in Britain, experts fear we are in ... massive death toll if the superbug took hold in hospitals. ...
... particular brain region predicts whether people tend to be ... Medical Center study were published in the Sunday, Jan ... ,"Although understanding the function of this brain region may ... it may give clues to the origins of important ...
... researchers from Wake Forest University School of Medicine, Radiation Therapy ... tamoxifen can dramatically reduce the risk of both cancer recurrence ... ,"While these treatments are standard care for ... are less likely to receive them," said lead author Ann ...
... youngsters are contracting tuberculosis, especially those in their 20s, due ... according to a report. ,Last year about ... ,According to the report of the Korea ... in 2006, an average of 115 people per day. ...
... control over choosing their breast cancer surgeon were more likely ... at a hospital affiliated with an accredited cancer program, compared ... health plan, according to a study led by researchers at ... study looked at 1,844 women recently diagnosed with breast cancer ...
Cached Medicine News:Health News:Buckyballs Used as 'Passkey' into Cancer Cells 2Health News:Activation of a Particular Brain Region Predicts Altruism: Study 2Health News:Cancer Recurrence in Older Breast Cancer Patients Reduced By Radiation Therapy 2Health News:More Youngsters Get Tuberculosis 2Health News:Are Women Seeing the Most Experienced Breast Cancer Surgeons? 2
... Gel Bed dimensions: 7.5cm(w) x 10cm(l). ... casting in the unit. Gel bed ... blue, yellow, pink, purple, or green. ... and dual sided combs, and Flip-Lid versions ...
... Submerged horizontal gels offer many advantages ... a primary tool for the molecular biologist. ... readily dissipate heat. These gels allow sample ... by wicks or sample well dehydration. Horizontal ...
... with 7 x 10 cm tray and ... gel electrophoresis of nucleic acids in mini ... The system includes an electrophoresis cell, 7 ... gates, mini-gel caster, and two 1.5 mm ...
... cell GT system, with 7 x ... submerged horizontal gel electrophoresis of nucleic ... 10 cm agarose gels. The system ... 10 cm UV-transparent gel tray, casting ...
Medicine Products: